1) 1984: US Patent # 4,473,640: “Detection of Morphine and its analogues using enzymatic hydrolysis”. Abstract: The invention relates to a method for hydrolyzing drug-glucuronic acid conjugates present in mammalian body fluids, the conjugates being derived from a narcotic analgesic, antagonist, or agonist-antagonist whose metabolism includes conjugation with glucuronic acid. The method comprises incubating the body fluid sample at from about 60.degree. to about 70.degree. C., for at least about 1 hour, with .beta.-glucuronidase derived from Patella vulgata, and substantially increases the sensitivity of chromatographic techniques for the detection of morphine and its analogues.
Type:Grant
Filed:June3, 1982
Date of Patent: September 25, 1984
Inventors: Joan D. Combie, Jerry W. Blake, Thomas E. Nugent, Thomas Tobin.

2) International Diagnostic Systems, 1987-1989; University of Kentucky licensing and royalty arrangements for fentanyl, carfentanil, furosemide, acepromazine, cocaine, detomidine, phenylbutazone, alfentanil, sufentanil and 20-plus other tests, in ELISA and PCFIA formats.

3) 1989: WTT ELISA Tests. Founder with David Watt and Dan Tai of first UK “Spin Off” company to distribute ELISA tests for use in racing horses and greyhounds. Sold to Neogen Corp, 1992, significant UK royalty.  Tests developed and brought to market include:

4) 1981, 1995: Publishing royalties:  “Drugs and the Performance Horse, 1981” and “Equine Drugs and Vaccines:  A Guide for Owners and Trainers, 1995.”

5) 1999: US Patent #5,883,095: “Formulations and methods to treat and prevent Equine Protozoal Myeloencephalitis” Abstract: The present invention provides formulations useful to treat EPM. It also provides methods to treat EPM in a horse in need of such treatment, comprising administering a pharmaceutically effective amount of a triazine-based anti-coccidial. Preferred are methods to treat EPM using clazuril, diclazuril, toltrazuril or letrazuril. The present invention also provides methods to prevent S. neurona infection in horses comprising administering a prophylactic amount of a triazine-based anticoccidial. Preferred is a method to prevent S. neurona infection by using clazuril, diclazuril, toltrazuril or letrazuril, alone or in combination with other known therapeutics.
Type: Grant
Filed: August 7, 1997
Date of Patent: March 16, 1999
Assignee: University of Kentucky Research Foundation
Inventors: David Granstrom, Thomas Tobin

6) Investigational New Animal Drug Applications: Formulations and methods to treat and prevent Equine Protozoal Myeloencephalitis. Investigational New Animal Drugs: two fast track/no environmental risk INADs for two agents for use in EPM.  US Patent #5,883,095 granted in this area; licensed to Bayer Animal Health, 1999, marketed as Marquisâ, August, 2001, first FDA approved treatment for EPM, more recently (Fall 2011) marketed as Protazil® by Merck Animal Health. Significant UK and Kentucky New Ace Corp patent royalty. 

7) 2003: Copyright: Unusual probabilistic mathematical analysis and biologically unique pathogenesis of MRLS copyrighted, US Copyright (US Copyright# TXU1111484).

8) 2004: US Patent Application number: 20040053938” “Novel method and device for treatment of exercise induced pulmonary hemorrhage in horses” Abstract: A device and method are provided for convenient, patient compliant inhalation therapy of equine species. The device can be used to deliver any drug or other pharmaceutical agent which can be adapted for inhalation directly into the nasal passages of a horse and thereby provide inhalation therapy with minimal discomfort. The device can be used to treat any of a number of conditions including, EIPH, infections and allergies, e.g., asthma or heaves. In one embodiment, the invention provides a method for the treatment or prevention of EIPH, utilizing a composition adapted for inhalant therapy comprised of sildenafil citrate alone or in combination other agents.
Type: Application
Filed: July 16, 2003
Publication date: March 18, 2004
Inventors: Calvert R. Bratton, Thomas Tobin

9) 2005: US Patent Application number: 20050043288 “Composition and  method for marking procaine penicillin” Abstract: A chemically marked procaine penicillin is provided as an antibiotic which can be distinguished from procaine used for anesthetic purposes. A preferred embodiment provides a procaine penicillin molecule wherein the procaine portion of the molecule comprises one or more substituted deuterium atoms in place of hydrogen atoms typically found in procaine penicillin. The resulting non-radioactive isotope can be easily identified via mass spectrometry as being distinct from any naturally occurring isotope, without negatively impacting the pharmacological nature of the drug itself. An alternative embodiment of the invention provides a method of marking the procaine penicillin through the substitution of various other isotopes in place of their naturally occurring counterparts. Methods of detection of the marked procaine penicillin molecule are also provided.
Type: Application
Filed: August 23, 2004
Publication date: February 24, 2005
Inventor: Thomas Tobin

10) 2006: US Patent # 7,074,834 for an equine tranquilizer (2006); “Long acting, reversible veterinary sedative and analgesic and method of use.” Abstract: A veterinary composition comprising a guanidine derivative, e.g., guanabenz or guanabenz acetate is provided which produces a rapid acting and long lasting sedative and analgesic effect in a subject animal that is selectively reversible. The use of guanabenz in the horse provides for a safe, effective, long lasting and rapidly reversible sedative and analgesic which can be used on the standing animal. Methods of use of the compositions of the invention are also provided.
Type: Grant
Filed: May 24, 2001
Date of Patent: July 11, 2006
Assignee: University of Kentucky Foundation
Inventor: Thomas Tobin

11) 1999: Equine Drug Metabolite Standards, Reference Standards, Stable Isotope Internal  Standards and Haptens: W. Karpiesiuk, F. Lehner, Eisenberg, R and Tobin, T have synthesized, purified and have licensed or are licensing the release of about 20 research quality equine metabolites standards and internal standards and haptens, modest UK royalty.

12) 2011: Equine Drug Metabolite Standards: 20 plus other Certified Reference Standards, Stable Isotope Internal Standards equine drug metabolite/regulatory analytes/deuterated standards certified reference standards, licensed to Frontier BioPharm, March 2011, modest UK royalty.

	Parent Medication	Regulatory Analyte/ Internal Standard
1	Acepromazine (metabolite)	1-Hydroxyethyl) promazine
2	Acepromazine (deuterated metabolite)	D4 2-(1-hydroxyethyl) promazine sulfoxide
3	Acepromazine (metabolite)	Acepromazine sulfoxide
4	Amitraz (deuterated metabolite)	D6 N-2,4-Dimethylphenyl-N’-methylformamidine
5	Bupivacaine (metabolite)	3-Hydroxybupivacaine
6	Chlorpromazine (metabolite)	7-Hydroxychlorpromazine
7	Clenbuterol (deuterated standard)	D9 Clenbuterol
8	Clenbuterol ( metabolite )	1-(4-Amino-3,5-Dichlorophenyl)ethane-1, 2-diol
9	Clenbuterol (metabolite)	2-(2-)4-Amino-3,5-Dicholorophenyl)-2-hydroxyethylamino)-2-Methyl-Propan-1-Ol
10	Colterol and Bitolterol (metabolite)	3-O-Methylcolterol
11	Carboxydetomidine	D4 Carboxydetomidine
12	Hydroxydetomidine	D4 Hydroxydetomidine
13	Fluphenazine (metabolite)	7-Hydroxyfluphenazine
14	Furosemide (deuterated standard)	D5 Furosemide
15	Flunixin (deuterated standard)	D3 Flunixin
16	Guafenesin (deuterated standard )	D4 Guafenesin
17	Guanabenz (metabolite)	Hydroxyguanabenz
18	Ketoprofen (deuterated standard )	D4 Ketoprofen
19	Lidocaine (deuterated metabolite)	D10 3-hydroxylidocaine
20	Lidocaine (metabolite)	3-Hydroxylidocaine
21	Mazindol (metabolite)	2-(2-Aminoethyl)-3-(4-chlorophenyl)-3-hydroxy-2,3-dihydro-isoindol-1-one
22	Mepivacaine (deuterated metabolite)	D3 3-Hydroxymepivacaine
23	Mepivacaine (metabolite)	3-Hydroxymepivacaine
24	Methocarbamol (deuterated metabolite)	D4 Methocarbamol
25	Phenylbutazone (deuterated metabolite)	D9 Phenylbutazone
26	Procaine (deuterated metabolite)	D10 Procaine
27	Promazine (metabolite)	3-Hydroxypromazine
28	Promethazine (metabolite)	Promethazine sulfoxide
29	Propanolol (metabolite)	4-Hydroxypropanolol
30	Propiomazine (metabolite)	2-(1-Hydroxypropyl) promethazine sulfoxide
31	Propionylpromazine (metabolite)	2-(1-Hydroxypropyl) promazine sulfoxide
32	Pyrilamine (deuterated standard)	D4 Pyrilamine
33	Pyrilamine (metabolite)	O-desmethylpyrilamine
34	Ropivacaine (metabolite)	3-Hydroxyropivacaine
35	Ropivacaine (metabolite)	4-Hydroxyropivacaine
36	Selegiline (metabolite)	Desmethylselegiline
37	Tramadol (metabolite)	Desmethyltramadol
38	Tripelennamine (metabolite)	3-OH-tripelennamine
39	Nandrolone	D3 Nandrolone